Home
Our Technology
Why It Matters
Our Leadership
Our Culture
News
Customer Portal
Join Us
Menu
Home
Our Technology
Why It Matters
Our Leadership
Our Culture
News
Customer Portal
Join Us
Icon-linkedin
News
CEGX presents sequencing technology at EACR Seville
Innovative Cancer Science 'CEGX scientists discussed novel sequencing technology for early cancer detection'
Read More
June 2022
Our Founder on Decoding DNA
Radio 4 Interview with Shankar Balasubramanian
Read More
March 2022
Cambridge Epigenetix Names Peter Fromen as Chief Executive Officer
Genomics Veteran to Lead Company Which Has a Commercial-Ready Novel Technology Platform that Can Realize the Largely Untapped Contribution of Epigenetics to Human Health
Read More
June 2022
Trinity in Japan Video Interview
Sir Shankar Balasubramanian, inventor of Next Generation DNA Sequencing (NGS)
View Video
Oct 2021
CEGX presents sequencing technology at Biology of Genomes 2022
CEGX scientists discussed novel technology at genomics conference in Cold Spring Harbour Laboratory
Read More
May 2022
Guardian Epigenetics Article
Epigenetics, the misunderstood science that could shed new light on ageing
Read More
Oct 2021
Article from Cancer Research UK Website
The award-winning researcher behind next generation sequencing (NGS)
Read More
Oct 2021
Series D Funding
Cambridge Epigenetix Raises $88 Million Series D Financing
Read More
Nov 2021
Series B funding – Google Ventures
Google Ventures leads $21M Series B in bioscience company Cambridge Epigenetix
Read More
March 2016
Headquarters
The Trinity Building, Chesterford Research Park, Cambridge, CB10 1XL, United Kingdom
info@cambridge-epigenetix.com
Careers: jobs@cegx.co.uk
+44 (0) 1223 800 700
Our Leadership
Our Culture
Our Technology
Why It Matters
News
Customer Portal
Employee Portal
Join Us
Privacy & Cookie Policy
Copyright © 2022 Cambridge Epigenetix, All rights reserved.